US Patent Issued to Synthekine on Oct. 21 for "GP130 binding molecules and methods of use" (California Inventors)

ALEXANDRIA, Va., Oct. 28 -- United States Patent no. 12,448,457, issued on Oct. 21, was assigned to Synthekine Inc. (Menlo Park, Calif.).

"GP130 binding molecules and methods of use" was invented by Robert Kastelein (Menlo Park, Calif.), Deepti Rokkam (Menlo Park, Calif.), Patrick J. Lupardus (Menlo Park, Calif.) and Sandro Vivona (Menlo Park, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to biologically active molecules comprising a single domain antibody (sdAb) that specifically binds to the extracellular domain of human gp130, compositions comprising such antibodies, and methods of use thereof."

The patent was filed on Aug. 4, 2021, under Application No. 18/006,189....